Tracers / [213Bi]Bi-PSMA-617
[213Bi]Bi-PSMA-617
Also written as PSMA-617; Pluvicto
- Radionuclide
- Bi-213 t½ 45.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting small molecule (urea-based PSMA ligand)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 28891033
- Clinical application
- Targeted alpha therapy of metastatic castration-resistant prostate cancer (dosimetry estimate) PMID 28891033
- Theranostic pair
- <a href="/tracers/in111-psma617/">in111-psma617</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 28891033 2018 Eur J Nucl Med Mol Imaging |
Need this precursor?We can point you to suppliers for [213Bi]Bi-PSMA-617, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111.